OUR FOCUS is on PN6047, a novel potent and selective, biased delta-opioid receptor agonist, which is predicted to reduce chronic pain and combat other conditions involving sensory hypersensitivity, including chronic cough and itch.

In pre-clinical studies, PN6047 has shown high potency and efficacy in reducing chronic pain without any indications of unwanted side effects.

PN6047 has an excellent pre-clinical safety profile and fully medicine-like properties predicting favourable dosing in humans. Its metabolic profile also indicates possibilities for developing combination therapies.

Find us

PharmNovo AB
Medicon Village AB
Scheeletorget 1
SE-223 81 Lund, Sweden